New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15–19 September) and published simultaneously in The Lancet shows that a much lower dose than previously thought of the old immunomodulatory drug anti-thymocyte globulin (ATG) is safe and effective in preventing progression of type 1 diabetes (T1D) in young people.
from Medical Xpress - latest medical and health news stories https://ift.tt/uBgtOzQ
